ProCE Banner Activity

ALINA: Randomized Phase III Trial of Adjuvant Alectinib vs Chemotherapy in Patients With Stage IB-IIIA ALK-Positive NSCLC

Conference Coverage

Alectinib showed a significant improvement in DFS compared with standard chemotherapy as adjuvant therapy in patients with stage IB-IIIA ALK-positive NSCLC (HR: 0.24; P <.0001).

Released: October 25, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc